Townsquare Capital LLC Makes New $1.11 Million Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Townsquare Capital LLC acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 12,386 shares of the medical equipment provider's stock, valued at approximately $1,108,000.

Other hedge funds have also modified their holdings of the company. Capital Fund Management S.A. raised its stake in Lantheus by 180.5% during the fourth quarter. Capital Fund Management S.A. now owns 99,573 shares of the medical equipment provider's stock valued at $8,908,000 after purchasing an additional 64,078 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Lantheus in the 4th quarter valued at about $36,183,000. Renaissance Group LLC grew its position in Lantheus by 54.3% in the fourth quarter. Renaissance Group LLC now owns 50,539 shares of the medical equipment provider's stock worth $4,521,000 after acquiring an additional 17,789 shares in the last quarter. Legal & General Group Plc grew its position in Lantheus by 2.1% in the fourth quarter. Legal & General Group Plc now owns 151,550 shares of the medical equipment provider's stock worth $13,558,000 after acquiring an additional 3,117 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in Lantheus by 9.6% during the fourth quarter. Federated Hermes Inc. now owns 315,718 shares of the medical equipment provider's stock worth $28,244,000 after acquiring an additional 27,615 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of LNTH stock traded up $4.01 during mid-day trading on Wednesday, hitting $103.58. The stock had a trading volume of 104,458 shares, compared to its average volume of 950,575. Lantheus Holdings, Inc. has a 12-month low of $62.59 and a 12-month high of $126.89. The firm's 50-day moving average is $96.11 and its two-hundred day moving average is $95.36. The firm has a market capitalization of $7.09 billion, a P/E ratio of 17.23 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on LNTH shares. JMP Securities reiterated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $129.43.

Insider Buying and Selling

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 over the last 90 days. Corporate insiders own 2.00% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.